Global Dementia Drugs Market by Drug Class (MAO Inhibitors, Glutamate Inhibitors, Cholinesterase Inhibitors), by Distribution Channel (Retail Pharmacies, Hospital Pharmacies), by Indication (Alzheimer’s Disease, Lewy Body Dementia, Parkinson’s Disease Dementia, Vascular Dementia) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast To 2028
Up Market Research published a new report titled “Dementia Drugs Market research report which is segmented by Drug Class (MAO Inhibitors, Glutamate Inhibitors, Cholinesterase Inhibitors), by Distribution Channel (Retail Pharmacies, Hospital Pharmacies), by Indication (Alzheimer’s Disease, Lewy Body Dementia, Parkinson’s Disease Dementia, Vascular Dementia), By Players/Companies Sanofi S.A., Janssen Pharmaceuticals Inc., Forest Laboratories Inc., F. Hoffmann-La Roche, Teva Pharmaceuticals, Aurobindo Pharma, Novartis AG, Biogen Pharmaceuticals, AstraZeneca, Eli Lilly and Company, Johnson and Johnson, Apotex Inc, Zydus Cadila, Pfizer Inc., Eisai Co. Ltd, Merck and Co. Inc., and Valeant Pharmaceutical International”. As per the study the market is expected to grow at a CAGR of XX% in the forecast period.
Report Scope
| Report Attributes | Report Details |
| Report Title | Dementia Drugs Market Research Report |
| By Drug Class | MAO Inhibitors, Glutamate Inhibitors, Cholinesterase Inhibitors |
| By Distribution Channel | Retail Pharmacies, Hospital Pharmacies |
| By Indication | Alzheimer’s Disease, Lewy Body Dementia, Parkinson’s Disease Dementia, Vascular Dementia |
| By Companies | Sanofi S.A., Janssen Pharmaceuticals Inc., Forest Laboratories Inc., F. Hoffmann-La Roche, Teva Pharmaceuticals, Aurobindo Pharma, Novartis AG, Biogen Pharmaceuticals, AstraZeneca, Eli Lilly and Company, Johnson and Johnson, Apotex Inc, Zydus Cadila, Pfizer Inc., Eisai Co. Ltd, Merck and Co. Inc., and Valeant Pharmaceutical International |
| Regions Covered | North America, Europe, APAC, Latin America, MEA |
| Base Year | 2020 |
| Historical Year | 2018 to 2019 (Data from 2010 can be provided as per availability) |
| Forecast Year | 2028 |
| Number of Pages | 236 |
| Number of Tables & Figures | 166 |
| Customization Available | Yes, the report can be customized as per your need. |
The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include products, applications, and competitor analysis.
Global Dementia Drugs Market Report Segments:
The market is segmented by Drug Class (MAO Inhibitors, Glutamate Inhibitors, Cholinesterase Inhibitors), by Distribution Channel (Retail Pharmacies, Hospital Pharmacies), by Indication (Alzheimer’s Disease, Lewy Body Dementia, Parkinson’s Disease Dementia, Vascular Dementia).
Some of the companies that are profiled in this report are:
- Sanofi S.A.
- Janssen Pharmaceuticals Inc.
- Forest Laboratories Inc.
- F. Hoffmann-La Roche
- Teva Pharmaceuticals
- Aurobindo Pharma
- Novartis AG
- Biogen Pharmaceuticals
- AstraZeneca
- Eli Lilly and Company
- Johnson and Johnson
- Apotex Inc
- Zydus Cadila
- Pfizer Inc.
- Eisai Co. Ltd
- Merck and Co. Inc., and Valeant Pharmaceutical International
Dementia Drugs Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.
Key Benefits for Industry Participants & Stakeholders:
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Dementia Drugs Market
Overview of the regional outlook of the Dementia Drugs Market:
Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA). North America region is further bifurcated into countries such as U.S., and Canada. The Europe region is further categorized into U.K., France, Germany, Italy, Spain, Russia, and Rest of Europe. Asia Pacific is further segmented into China, Japan, South Korea, India, Australia, South East Asia, and Rest of Asia Pacific. Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa, and Rest of MEA.
Highlights of The Dementia Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of Dementia Drugs Market.
- Historical data and forecast.
- Estimations for the forecast period 2028.
- Developments and trends in the market.
1. MAO Inhibitors
2. Glutamate Inhibitors
3. Cholinesterase Inhibitors
7. By Distribution Channel:1. Retail Pharmacies
2. Hospital Pharmacies
8. By Indication:1. Alzheimer’s Disease
2. Lewy Body Dementia
3. Parkinson’s Disease Dementia
4. Vascular Dementia
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Dementia Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
Reasons to Purchase the Dementia Drugs Market Report:
- The report includes a plethora of information such as market dynamics scenario and opportunities during the forecast period
- Segments and sub-segments include quantitative, qualitative, value (USD Million,) and volume (Units Million) data.
- Regional, sub-regional, and country level data includes the demand and supply forces along with their influence on the market.
- The competitive landscape comprises share of key players, new developments, and strategies in the last three years.
- Comprehensive companies offering products, relevant financial information, recent developments, SWOT analysis, and strategies by these players.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Dementia Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Dementia Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Dementia Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Dementia Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Dementia Drugs Market Size & Forecast, 2018-2028
4.5.1 Dementia Drugs Market Size and Y-o-Y Growth
4.5.2 Dementia Drugs Market Absolute $ Opportunity
Chapter 5 Global Dementia Drugs Market Analysis and Forecast by Drug Class
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Drug Class
5.1.2 Basis Point Share (BPS) Analysis by Drug Class
5.1.3 Absolute $ Opportunity Assessment by Drug Class
5.2 Dementia Drugs Market Size Forecast by Drug Class
5.2.1 MAO Inhibitors
5.2.2 Glutamate Inhibitors
5.2.3 Cholinesterase Inhibitors
5.3 Market Attractiveness Analysis by Drug Class
Chapter 6 Global Dementia Drugs Market Analysis and Forecast by Distribution Channel
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Distribution Channel
6.1.2 Basis Point Share (BPS) Analysis by Distribution Channel
6.1.3 Absolute $ Opportunity Assessment by Distribution Channel
6.2 Dementia Drugs Market Size Forecast by Distribution Channel
6.2.1 Retail Pharmacies
6.2.2 Hospital Pharmacies
6.3 Market Attractiveness Analysis by Distribution Channel
Chapter 7 Global Dementia Drugs Market Analysis and Forecast by Indication
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Indication
7.1.2 Basis Point Share (BPS) Analysis by Indication
7.1.3 Absolute $ Opportunity Assessment by Indication
7.2 Dementia Drugs Market Size Forecast by Indication
7.2.1 Alzheimer’s Disease
7.2.2 Lewy Body Dementia
7.2.3 Parkinson’s Disease Dementia
7.2.4 Vascular Dementia
7.3 Market Attractiveness Analysis by Indication
Chapter 8 Global Dementia Drugs Market Analysis and Forecast by Region
8.1 Introduction
8.1.1 Key Market Trends & Growth Opportunities by Region
8.1.2 Basis Point Share (BPS) Analysis by Region
8.1.3 Absolute $ Opportunity Assessment by Region
8.2 Dementia Drugs Market Size Forecast by Region
8.2.1 North America
8.2.2 Europe
8.2.3 Asia Pacific
8.2.4 Latin America
8.2.5 Middle East & Africa (MEA)
8.3 Market Attractiveness Analysis by Region
Chapter 9 Coronavirus Disease (COVID-19) Impact
9.1 Introduction
9.2 Current & Future Impact Analysis
9.3 Economic Impact Analysis
9.4 Government Policies
9.5 Investment Scenario
Chapter 10 North America Dementia Drugs Analysis and Forecast
10.1 Introduction
10.2 North America Dementia Drugs Market Size Forecast by Country
10.2.1 U.S.
10.2.2 Canada
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 North America Dementia Drugs Market Size Forecast by Drug Class
10.6.1 MAO Inhibitors
10.6.2 Glutamate Inhibitors
10.6.3 Cholinesterase Inhibitors
10.7 Basis Point Share (BPS) Analysis by Drug Class
10.8 Absolute $ Opportunity Assessment by Drug Class
10.9 Market Attractiveness Analysis by Drug Class
10.10 North America Dementia Drugs Market Size Forecast by Distribution Channel
10.10.1 Retail Pharmacies
10.10.2 Hospital Pharmacies
10.11 Basis Point Share (BPS) Analysis by Distribution Channel
10.12 Absolute $ Opportunity Assessment by Distribution Channel
10.13 Market Attractiveness Analysis by Distribution Channel
10.14 North America Dementia Drugs Market Size Forecast by Indication
10.14.1 Alzheimer’s Disease
10.14.2 Lewy Body Dementia
10.14.3 Parkinson’s Disease Dementia
10.14.4 Vascular Dementia
10.15 Basis Point Share (BPS) Analysis by Indication
10.16 Absolute $ Opportunity Assessment by Indication
10.17 Market Attractiveness Analysis by Indication
Chapter 11 Europe Dementia Drugs Analysis and Forecast
11.1 Introduction
11.2 Europe Dementia Drugs Market Size Forecast by Country
11.2.1 Germany
11.2.2 France
11.2.3 Italy
11.2.4 U.K.
11.2.5 Spain
11.2.6 Russia
11.2.7 Rest of Europe
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Europe Dementia Drugs Market Size Forecast by Drug Class
11.6.1 MAO Inhibitors
11.6.2 Glutamate Inhibitors
11.6.3 Cholinesterase Inhibitors
11.7 Basis Point Share (BPS) Analysis by Drug Class
11.8 Absolute $ Opportunity Assessment by Drug Class
11.9 Market Attractiveness Analysis by Drug Class
11.10 Europe Dementia Drugs Market Size Forecast by Distribution Channel
11.10.1 Retail Pharmacies
11.10.2 Hospital Pharmacies
11.11 Basis Point Share (BPS) Analysis by Distribution Channel
11.12 Absolute $ Opportunity Assessment by Distribution Channel
11.13 Market Attractiveness Analysis by Distribution Channel
11.14 Europe Dementia Drugs Market Size Forecast by Indication
11.14.1 Alzheimer’s Disease
11.14.2 Lewy Body Dementia
11.14.3 Parkinson’s Disease Dementia
11.14.4 Vascular Dementia
11.15 Basis Point Share (BPS) Analysis by Indication
11.16 Absolute $ Opportunity Assessment by Indication
11.17 Market Attractiveness Analysis by Indication
Chapter 12 Asia Pacific Dementia Drugs Analysis and Forecast
12.1 Introduction
12.2 Asia Pacific Dementia Drugs Market Size Forecast by Country
12.2.1 China
12.2.2 Japan
12.2.3 South Korea
12.2.4 India
12.2.5 Australia
12.2.6 South East Asia (SEA)
12.2.7 Rest of Asia Pacific (APAC)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Asia Pacific Dementia Drugs Market Size Forecast by Drug Class
12.6.1 MAO Inhibitors
12.6.2 Glutamate Inhibitors
12.6.3 Cholinesterase Inhibitors
12.7 Basis Point Share (BPS) Analysis by Drug Class
12.8 Absolute $ Opportunity Assessment by Drug Class
12.9 Market Attractiveness Analysis by Drug Class
12.10 Asia Pacific Dementia Drugs Market Size Forecast by Distribution Channel
12.10.1 Retail Pharmacies
12.10.2 Hospital Pharmacies
12.11 Basis Point Share (BPS) Analysis by Distribution Channel
12.12 Absolute $ Opportunity Assessment by Distribution Channel
12.13 Market Attractiveness Analysis by Distribution Channel
12.14 Asia Pacific Dementia Drugs Market Size Forecast by Indication
12.14.1 Alzheimer’s Disease
12.14.2 Lewy Body Dementia
12.14.3 Parkinson’s Disease Dementia
12.14.4 Vascular Dementia
12.15 Basis Point Share (BPS) Analysis by Indication
12.16 Absolute $ Opportunity Assessment by Indication
12.17 Market Attractiveness Analysis by Indication
Chapter 13 Latin America Dementia Drugs Analysis and Forecast
13.1 Introduction
13.2 Latin America Dementia Drugs Market Size Forecast by Country
13.2.1 Brazil
13.2.2 Mexico
13.2.3 Rest of Latin America (LATAM)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Latin America Dementia Drugs Market Size Forecast by Drug Class
13.6.1 MAO Inhibitors
13.6.2 Glutamate Inhibitors
13.6.3 Cholinesterase Inhibitors
13.7 Basis Point Share (BPS) Analysis by Drug Class
13.8 Absolute $ Opportunity Assessment by Drug Class
13.9 Market Attractiveness Analysis by Drug Class
13.10 Latin America Dementia Drugs Market Size Forecast by Distribution Channel
13.10.1 Retail Pharmacies
13.10.2 Hospital Pharmacies
13.11 Basis Point Share (BPS) Analysis by Distribution Channel
13.12 Absolute $ Opportunity Assessment by Distribution Channel
13.13 Market Attractiveness Analysis by Distribution Channel
13.14 Latin America Dementia Drugs Market Size Forecast by Indication
13.14.1 Alzheimer’s Disease
13.14.2 Lewy Body Dementia
13.14.3 Parkinson’s Disease Dementia
13.14.4 Vascular Dementia
13.15 Basis Point Share (BPS) Analysis by Indication
13.16 Absolute $ Opportunity Assessment by Indication
13.17 Market Attractiveness Analysis by Indication
Chapter 14 Middle East & Africa (MEA) Dementia Drugs Analysis and Forecast
14.1 Introduction
14.2 Middle East & Africa (MEA) Dementia Drugs Market Size Forecast by Country
14.2.1 Saudi Arabia
14.2.2 South Africa
14.2.3 UAE
14.2.4 Rest of Middle East & Africa (MEA)
14.3 Basis Point Share (BPS) Analysis by Country
14.4 Absolute $ Opportunity Assessment by Country
14.5 Market Attractiveness Analysis by Country
14.6 Middle East & Africa (MEA) Dementia Drugs Market Size Forecast by Drug Class
14.6.1 MAO Inhibitors
14.6.2 Glutamate Inhibitors
14.6.3 Cholinesterase Inhibitors
14.7 Basis Point Share (BPS) Analysis by Drug Class
14.8 Absolute $ Opportunity Assessment by Drug Class
14.9 Market Attractiveness Analysis by Drug Class
14.10 Middle East & Africa (MEA) Dementia Drugs Market Size Forecast by Distribution Channel
14.10.1 Retail Pharmacies
14.10.2 Hospital Pharmacies
14.11 Basis Point Share (BPS) Analysis by Distribution Channel
14.12 Absolute $ Opportunity Assessment by Distribution Channel
14.13 Market Attractiveness Analysis by Distribution Channel
14.14 Middle East & Africa (MEA) Dementia Drugs Market Size Forecast by Indication
14.14.1 Alzheimer’s Disease
14.14.2 Lewy Body Dementia
14.14.3 Parkinson’s Disease Dementia
14.14.4 Vascular Dementia
14.15 Basis Point Share (BPS) Analysis by Indication
14.16 Absolute $ Opportunity Assessment by Indication
14.17 Market Attractiveness Analysis by Indication
Chapter 15 Competition Landscape
15.1 Dementia Drugs Market: Competitive Dashboard
15.2 Global Dementia Drugs Market: Market Share Analysis, 2019
15.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
15.3.1 Sanofi S.A.
15.3.2 Janssen Pharmaceuticals Inc.
15.3.3 Forest Laboratories Inc.
15.3.4 F. Hoffmann-La Roche
15.3.5 Teva Pharmaceuticals
15.3.6 Aurobindo Pharma
15.3.7 Novartis AG
15.3.8 Biogen Pharmaceuticals
15.3.9 AstraZeneca
15.3.10 Eli Lilly and Company
15.3.11 Johnson and Johnson
15.3.12 Apotex Inc
15.3.13 Zydus Cadila
15.3.14 Pfizer Inc.
15.3.15 Eisai Co. Ltd
15.3.16 Merck and Co. Inc., and Valeant Pharmaceutical International
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Dementia Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Dementia Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Dementia Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Dementia Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Dementia Drugs Market Size & Forecast, 2018-2028
4.5.1 Dementia Drugs Market Size and Y-o-Y Growth
4.5.2 Dementia Drugs Market Absolute $ Opportunity
Chapter 5 Global Dementia Drugs Market Analysis and Forecast by Drug Class
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Drug Class
5.1.2 Basis Point Share (BPS) Analysis by Drug Class
5.1.3 Absolute $ Opportunity Assessment by Drug Class
5.2 Dementia Drugs Market Size Forecast by Drug Class
5.2.1 MAO Inhibitors
5.2.2 Glutamate Inhibitors
5.2.3 Cholinesterase Inhibitors
5.3 Market Attractiveness Analysis by Drug Class
Chapter 6 Global Dementia Drugs Market Analysis and Forecast by Distribution Channel
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Distribution Channel
6.1.2 Basis Point Share (BPS) Analysis by Distribution Channel
6.1.3 Absolute $ Opportunity Assessment by Distribution Channel
6.2 Dementia Drugs Market Size Forecast by Distribution Channel
6.2.1 Retail Pharmacies
6.2.2 Hospital Pharmacies
6.3 Market Attractiveness Analysis by Distribution Channel
Chapter 7 Global Dementia Drugs Market Analysis and Forecast by Indication
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Indication
7.1.2 Basis Point Share (BPS) Analysis by Indication
7.1.3 Absolute $ Opportunity Assessment by Indication
7.2 Dementia Drugs Market Size Forecast by Indication
7.2.1 Alzheimer’s Disease
7.2.2 Lewy Body Dementia
7.2.3 Parkinson’s Disease Dementia
7.2.4 Vascular Dementia
7.3 Market Attractiveness Analysis by Indication
Chapter 8 Global Dementia Drugs Market Analysis and Forecast by Region
8.1 Introduction
8.1.1 Key Market Trends & Growth Opportunities by Region
8.1.2 Basis Point Share (BPS) Analysis by Region
8.1.3 Absolute $ Opportunity Assessment by Region
8.2 Dementia Drugs Market Size Forecast by Region
8.2.1 North America
8.2.2 Europe
8.2.3 Asia Pacific
8.2.4 Latin America
8.2.5 Middle East & Africa (MEA)
8.3 Market Attractiveness Analysis by Region
Chapter 9 Coronavirus Disease (COVID-19) Impact
9.1 Introduction
9.2 Current & Future Impact Analysis
9.3 Economic Impact Analysis
9.4 Government Policies
9.5 Investment Scenario
Chapter 10 North America Dementia Drugs Analysis and Forecast
10.1 Introduction
10.2 North America Dementia Drugs Market Size Forecast by Country
10.2.1 U.S.
10.2.2 Canada
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 North America Dementia Drugs Market Size Forecast by Drug Class
10.6.1 MAO Inhibitors
10.6.2 Glutamate Inhibitors
10.6.3 Cholinesterase Inhibitors
10.7 Basis Point Share (BPS) Analysis by Drug Class
10.8 Absolute $ Opportunity Assessment by Drug Class
10.9 Market Attractiveness Analysis by Drug Class
10.10 North America Dementia Drugs Market Size Forecast by Distribution Channel
10.10.1 Retail Pharmacies
10.10.2 Hospital Pharmacies
10.11 Basis Point Share (BPS) Analysis by Distribution Channel
10.12 Absolute $ Opportunity Assessment by Distribution Channel
10.13 Market Attractiveness Analysis by Distribution Channel
10.14 North America Dementia Drugs Market Size Forecast by Indication
10.14.1 Alzheimer’s Disease
10.14.2 Lewy Body Dementia
10.14.3 Parkinson’s Disease Dementia
10.14.4 Vascular Dementia
10.15 Basis Point Share (BPS) Analysis by Indication
10.16 Absolute $ Opportunity Assessment by Indication
10.17 Market Attractiveness Analysis by Indication
Chapter 11 Europe Dementia Drugs Analysis and Forecast
11.1 Introduction
11.2 Europe Dementia Drugs Market Size Forecast by Country
11.2.1 Germany
11.2.2 France
11.2.3 Italy
11.2.4 U.K.
11.2.5 Spain
11.2.6 Russia
11.2.7 Rest of Europe
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Europe Dementia Drugs Market Size Forecast by Drug Class
11.6.1 MAO Inhibitors
11.6.2 Glutamate Inhibitors
11.6.3 Cholinesterase Inhibitors
11.7 Basis Point Share (BPS) Analysis by Drug Class
11.8 Absolute $ Opportunity Assessment by Drug Class
11.9 Market Attractiveness Analysis by Drug Class
11.10 Europe Dementia Drugs Market Size Forecast by Distribution Channel
11.10.1 Retail Pharmacies
11.10.2 Hospital Pharmacies
11.11 Basis Point Share (BPS) Analysis by Distribution Channel
11.12 Absolute $ Opportunity Assessment by Distribution Channel
11.13 Market Attractiveness Analysis by Distribution Channel
11.14 Europe Dementia Drugs Market Size Forecast by Indication
11.14.1 Alzheimer’s Disease
11.14.2 Lewy Body Dementia
11.14.3 Parkinson’s Disease Dementia
11.14.4 Vascular Dementia
11.15 Basis Point Share (BPS) Analysis by Indication
11.16 Absolute $ Opportunity Assessment by Indication
11.17 Market Attractiveness Analysis by Indication
Chapter 12 Asia Pacific Dementia Drugs Analysis and Forecast
12.1 Introduction
12.2 Asia Pacific Dementia Drugs Market Size Forecast by Country
12.2.1 China
12.2.2 Japan
12.2.3 South Korea
12.2.4 India
12.2.5 Australia
12.2.6 South East Asia (SEA)
12.2.7 Rest of Asia Pacific (APAC)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Asia Pacific Dementia Drugs Market Size Forecast by Drug Class
12.6.1 MAO Inhibitors
12.6.2 Glutamate Inhibitors
12.6.3 Cholinesterase Inhibitors
12.7 Basis Point Share (BPS) Analysis by Drug Class
12.8 Absolute $ Opportunity Assessment by Drug Class
12.9 Market Attractiveness Analysis by Drug Class
12.10 Asia Pacific Dementia Drugs Market Size Forecast by Distribution Channel
12.10.1 Retail Pharmacies
12.10.2 Hospital Pharmacies
12.11 Basis Point Share (BPS) Analysis by Distribution Channel
12.12 Absolute $ Opportunity Assessment by Distribution Channel
12.13 Market Attractiveness Analysis by Distribution Channel
12.14 Asia Pacific Dementia Drugs Market Size Forecast by Indication
12.14.1 Alzheimer’s Disease
12.14.2 Lewy Body Dementia
12.14.3 Parkinson’s Disease Dementia
12.14.4 Vascular Dementia
12.15 Basis Point Share (BPS) Analysis by Indication
12.16 Absolute $ Opportunity Assessment by Indication
12.17 Market Attractiveness Analysis by Indication
Chapter 13 Latin America Dementia Drugs Analysis and Forecast
13.1 Introduction
13.2 Latin America Dementia Drugs Market Size Forecast by Country
13.2.1 Brazil
13.2.2 Mexico
13.2.3 Rest of Latin America (LATAM)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Latin America Dementia Drugs Market Size Forecast by Drug Class
13.6.1 MAO Inhibitors
13.6.2 Glutamate Inhibitors
13.6.3 Cholinesterase Inhibitors
13.7 Basis Point Share (BPS) Analysis by Drug Class
13.8 Absolute $ Opportunity Assessment by Drug Class
13.9 Market Attractiveness Analysis by Drug Class
13.10 Latin America Dementia Drugs Market Size Forecast by Distribution Channel
13.10.1 Retail Pharmacies
13.10.2 Hospital Pharmacies
13.11 Basis Point Share (BPS) Analysis by Distribution Channel
13.12 Absolute $ Opportunity Assessment by Distribution Channel
13.13 Market Attractiveness Analysis by Distribution Channel
13.14 Latin America Dementia Drugs Market Size Forecast by Indication
13.14.1 Alzheimer’s Disease
13.14.2 Lewy Body Dementia
13.14.3 Parkinson’s Disease Dementia
13.14.4 Vascular Dementia
13.15 Basis Point Share (BPS) Analysis by Indication
13.16 Absolute $ Opportunity Assessment by Indication
13.17 Market Attractiveness Analysis by Indication
Chapter 14 Middle East & Africa (MEA) Dementia Drugs Analysis and Forecast
14.1 Introduction
14.2 Middle East & Africa (MEA) Dementia Drugs Market Size Forecast by Country
14.2.1 Saudi Arabia
14.2.2 South Africa
14.2.3 UAE
14.2.4 Rest of Middle East & Africa (MEA)
14.3 Basis Point Share (BPS) Analysis by Country
14.4 Absolute $ Opportunity Assessment by Country
14.5 Market Attractiveness Analysis by Country
14.6 Middle East & Africa (MEA) Dementia Drugs Market Size Forecast by Drug Class
14.6.1 MAO Inhibitors
14.6.2 Glutamate Inhibitors
14.6.3 Cholinesterase Inhibitors
14.7 Basis Point Share (BPS) Analysis by Drug Class
14.8 Absolute $ Opportunity Assessment by Drug Class
14.9 Market Attractiveness Analysis by Drug Class
14.10 Middle East & Africa (MEA) Dementia Drugs Market Size Forecast by Distribution Channel
14.10.1 Retail Pharmacies
14.10.2 Hospital Pharmacies
14.11 Basis Point Share (BPS) Analysis by Distribution Channel
14.12 Absolute $ Opportunity Assessment by Distribution Channel
14.13 Market Attractiveness Analysis by Distribution Channel
14.14 Middle East & Africa (MEA) Dementia Drugs Market Size Forecast by Indication
14.14.1 Alzheimer’s Disease
14.14.2 Lewy Body Dementia
14.14.3 Parkinson’s Disease Dementia
14.14.4 Vascular Dementia
14.15 Basis Point Share (BPS) Analysis by Indication
14.16 Absolute $ Opportunity Assessment by Indication
14.17 Market Attractiveness Analysis by Indication
Chapter 15 Competition Landscape
15.1 Dementia Drugs Market: Competitive Dashboard
15.2 Global Dementia Drugs Market: Market Share Analysis, 2019
15.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
15.3.1 Sanofi S.A.
15.3.2 Janssen Pharmaceuticals Inc.
15.3.3 Forest Laboratories Inc.
15.3.4 F. Hoffmann-La Roche
15.3.5 Teva Pharmaceuticals
15.3.6 Aurobindo Pharma
15.3.7 Novartis AG
15.3.8 Biogen Pharmaceuticals
15.3.9 AstraZeneca
15.3.10 Eli Lilly and Company
15.3.11 Johnson and Johnson
15.3.12 Apotex Inc
15.3.13 Zydus Cadila
15.3.14 Pfizer Inc.
15.3.15 Eisai Co. Ltd
15.3.16 Merck and Co. Inc., and Valeant Pharmaceutical International
Segments Covered in the Report
The global Dementia Drugs market has been segmented based on
By Drug Class
The global Dementia Drugs market has been segmented based on
By Drug Class
- MAO Inhibitors
- Glutamate Inhibitors
- Cholinesterase Inhibitors
- Retail Pharmacies
- Hospital Pharmacies
- Alzheimer’s Disease
- Lewy Body Dementia
- Parkinson’s Disease Dementia
- Vascular Dementia
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
- Sanofi S.A.
- Janssen Pharmaceuticals Inc.
- Forest Laboratories Inc.
- F. Hoffmann-La Roche
- Teva Pharmaceuticals
- Aurobindo Pharma
- Novartis AG
- Biogen Pharmaceuticals
- AstraZeneca
- Eli Lilly and Company
- Johnson and Johnson
- Apotex Inc
- Zydus Cadila
- Pfizer Inc.
- Eisai Co. Ltd
- Merck and Co. Inc., and Valeant Pharmaceutical International
Our Clients
Related Reports
Some other reports from this category!
